BRPI0817427A8 - anticorpo anti-bst2 - Google Patents
anticorpo anti-bst2Info
- Publication number
- BRPI0817427A8 BRPI0817427A8 BRPI0817427A BRPI0817427A BRPI0817427A8 BR PI0817427 A8 BRPI0817427 A8 BR PI0817427A8 BR PI0817427 A BRPI0817427 A BR PI0817427A BR PI0817427 A BRPI0817427 A BR PI0817427A BR PI0817427 A8 BRPI0817427 A8 BR PI0817427A8
- Authority
- BR
- Brazil
- Prior art keywords
- present
- antibodies
- bst2
- antibody
- bst2d
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007269470 | 2007-10-16 | ||
PCT/JP2008/068794 WO2009051201A1 (ja) | 2007-10-16 | 2008-10-16 | 抗bst2抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0817427A2 BRPI0817427A2 (pt) | 2015-06-16 |
BRPI0817427A8 true BRPI0817427A8 (pt) | 2019-01-29 |
Family
ID=40567462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0817427A BRPI0817427A8 (pt) | 2007-10-16 | 2008-10-16 | anticorpo anti-bst2 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8529896B2 (pt) |
EP (1) | EP2210939A4 (pt) |
JP (1) | JP5558825B2 (pt) |
KR (1) | KR20100090258A (pt) |
CN (2) | CN104031150A (pt) |
AU (1) | AU2008312858A1 (pt) |
BR (1) | BRPI0817427A8 (pt) |
CA (1) | CA2702939A1 (pt) |
HK (1) | HK1153502A1 (pt) |
IL (1) | IL205073A (pt) |
MX (1) | MX2010004251A (pt) |
NZ (1) | NZ585394A (pt) |
RU (1) | RU2010119450A (pt) |
UA (1) | UA105760C2 (pt) |
WO (1) | WO2009051201A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
WO2014066271A1 (en) * | 2012-10-22 | 2014-05-01 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
RU2722212C9 (ru) * | 2014-08-05 | 2020-07-23 | СиБи ТЕРЕПЬЮТИКС, ИНК. | Анти-pd-l1 антитела |
US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
CN107619443B (zh) * | 2016-07-14 | 2020-08-14 | 深圳宾德生物技术有限公司 | 抗人和鼠cd317的单克隆抗体及其制备方法和应用 |
EP4168029A1 (en) * | 2020-06-19 | 2023-04-26 | Board of Regents, The University of Texas System | Anti-bst2 antibodies targeting bst2 long isoform |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US305121A (en) * | 1884-09-16 | Razor-strop | ||
ZA948016B (en) * | 1993-10-15 | 1995-05-31 | Toshio Hirano | A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof |
US6503510B2 (en) | 1997-02-12 | 2003-01-07 | Chugai Seiyaku Kabushiki Kaisha | Remedies for lymphocytic tumors |
ATE317900T1 (de) | 1998-02-25 | 2006-03-15 | Chugai Pharmaceutical Co Ltd | Für hm1.24 antigen kodierendes gen und dessen promotor |
JP4450555B2 (ja) * | 2000-12-28 | 2010-04-14 | 協和発酵キリン株式会社 | 新規モノクローナル抗体 |
EP1364657B1 (en) | 2001-02-07 | 2016-12-28 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myelocytic leukemia |
US7776612B2 (en) | 2001-04-13 | 2010-08-17 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying antigen expression |
US8603481B2 (en) | 2003-10-10 | 2013-12-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for solid tumors |
WO2006008886A1 (ja) | 2004-06-11 | 2006-01-26 | Ginkgo Biomedical Research Institute Co., Ltd. | インターフェロン産生細胞の活性調節剤 |
WO2006013923A1 (ja) * | 2004-08-05 | 2006-02-09 | Ginkgo Biomedical Research Institute Co., Ltd. | 自己免疫疾患を伴う関節炎の治療剤 |
JPWO2006054748A1 (ja) | 2004-11-22 | 2008-06-05 | Sbiバイオテック株式会社 | 腎炎の治療剤 |
US20080299128A1 (en) | 2006-06-20 | 2008-12-04 | Myung Kim | Effect of Bst2 on inflammation |
-
2008
- 2008-10-16 US US12/738,285 patent/US8529896B2/en not_active Expired - Fee Related
- 2008-10-16 JP JP2009538149A patent/JP5558825B2/ja not_active Expired - Fee Related
- 2008-10-16 AU AU2008312858A patent/AU2008312858A1/en not_active Abandoned
- 2008-10-16 BR BRPI0817427A patent/BRPI0817427A8/pt not_active IP Right Cessation
- 2008-10-16 WO PCT/JP2008/068794 patent/WO2009051201A1/ja active Application Filing
- 2008-10-16 RU RU2010119450/10A patent/RU2010119450A/ru unknown
- 2008-10-16 CN CN201410162825.3A patent/CN104031150A/zh active Pending
- 2008-10-16 KR KR1020107010635A patent/KR20100090258A/ko not_active Application Discontinuation
- 2008-10-16 NZ NZ585394A patent/NZ585394A/en not_active IP Right Cessation
- 2008-10-16 MX MX2010004251A patent/MX2010004251A/es active IP Right Grant
- 2008-10-16 UA UAA201005531A patent/UA105760C2/uk unknown
- 2008-10-16 EP EP08838804A patent/EP2210939A4/en not_active Withdrawn
- 2008-10-16 CA CA2702939A patent/CA2702939A1/en not_active Abandoned
- 2008-10-16 CN CN200880122043.XA patent/CN101952426B/zh not_active Expired - Fee Related
-
2010
- 2010-04-14 IL IL205073A patent/IL205073A/en not_active IP Right Cessation
-
2011
- 2011-07-18 HK HK11107441.7A patent/HK1153502A1/xx not_active IP Right Cessation
-
2013
- 2013-08-22 US US13/973,930 patent/US20130336967A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0817427A2 (pt) | 2015-06-16 |
KR20100090258A (ko) | 2010-08-13 |
RU2010119450A (ru) | 2011-11-27 |
IL205073A (en) | 2014-07-31 |
MX2010004251A (es) | 2010-08-30 |
UA105760C2 (uk) | 2014-06-25 |
US20130336967A1 (en) | 2013-12-19 |
EP2210939A4 (en) | 2012-08-08 |
WO2009051201A1 (ja) | 2009-04-23 |
IL205073A0 (en) | 2010-11-30 |
AU2008312858A1 (en) | 2009-04-23 |
CN101952426B (zh) | 2014-04-16 |
JPWO2009051201A1 (ja) | 2011-03-03 |
CN104031150A (zh) | 2014-09-10 |
HK1153502A1 (en) | 2012-03-30 |
CN101952426A (zh) | 2011-01-19 |
JP5558825B2 (ja) | 2014-07-23 |
US8529896B2 (en) | 2013-09-10 |
US20100278832A1 (en) | 2010-11-04 |
CA2702939A1 (en) | 2009-04-23 |
EP2210939A1 (en) | 2010-07-28 |
NZ585394A (en) | 2012-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0817427A8 (pt) | anticorpo anti-bst2 | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
BR112014019116A8 (pt) | Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo | |
AR092612A1 (es) | Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos | |
BR112012012887A2 (pt) | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. | |
AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
CR20190440A (es) | Receptores de unión a antígeno mejorados | |
BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
BR112014018561A8 (pt) | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo | |
AR063840A1 (es) | Anticuerpos humanos monoclonales para btla y metodos de uso | |
BRPI0613279A8 (pt) | Anticorpo manoclonal isolado, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-cd19, método para inibir o crescimento de células tumorais expressando cd19, e método para depleção de celulas b num indivíduo | |
EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
AR073775A1 (es) | Anticuerpos biespecificos anti-vegf/anti- ang -2 | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
BR112013027867A2 (pt) | "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit" | |
BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
BRPI0808940B8 (pt) | anticorpo humano-murino quimérico ou xegogeneico, humanizado, humano ou seu fragmento de ligação, vetor de expressão, microrganismo transgênico, método para preparar um anticorpo ou um fragmento de ligação, composição, composição de diagnóstico, uso do anticorpo ou fragmento de ligação, kit para o diagnóstico de um tumor e uso da molécula de antígeno ligante ao tumor | |
MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
BR112015008347A2 (pt) | molécula de anticorpo isolada, uso de dita molécula de anticorpo, composição, ácido nucleico isolado, célula hospedeira, métodos para produção de uma molécula de anticorpo, para produzir um domínio de ligação de antígeno ao anticorpo para a?1-42 humano e para produzir um membro de ligação que se liga a a?1-42 humana. | |
EA201491977A1 (ru) | Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии | |
FR2933773B1 (fr) | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal | |
EA201071068A1 (ru) | Антитела к tyrp1 | |
AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B25C | Requirement related to requested transfer of rights |
Owner name: SBI BIOTECH CO., LTD. (JP) , CHUGAI SEIYAKU KABUSH Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20120000079/RJ DE 02/01/2012, E NECESSARIO APRESENTAR COMPLEMENTACAO DO VALOR DA GUIA RELATIVA AO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
B25B | Requested transfer of rights rejected |
Owner name: SBI BIOTECH CO., LTD. (JP) , CHUGAI SEIYAKU KABUSH |